Nasdaq Stockholm AB: Delisting of paid subscription units in Xbrane Biopharma AB

The paid subscription units in Xbrane Biopharma AB will be delisted. Last
trading day for XBRANE BTUwill be on March 20, 2024. 



Instrument:  Paid subscription units
--------------------------------------
Short name:  XBRANE BTU       
--------------------------------------
ISIN code:   SE0021515111      
--------------------------------------
Orderbook ID: 325545         
--------------------------------------



For further information concerning this exchange notice please contact Listing
Qualifications on telephone +46 8 405 7280, or iss@nasdaq.com.

5 heiße Wetten für den Jahresendspurt!

Nach dem unerwartet schnellen Ende der US-Wahlen mit dem Sieg des republikanischen Kandidaten Donald Trump fackelten die Aktien- und Krypto- Märkte ein wahres Kursfeuerwerk ab und bliesen zur Jahresendrallye.

Im aktuellen kostenlosen Report beleuchten wir 5 aussichtsreiche Unternehmen, die das Fundament besitzen, in den nächsten Monaten den breiten Markt zu schlagen.

Seien Sie dabei!

Fordern Sie jetzt unseren brandneuen neuen Spezialreport an und erfahren Sie, welche Aktien aufgrund ihrer Bewertung sowie charttechnischen Situation das Potenzial zu einer Outperformance besitzen.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Hier klicken

Zeit	Aktuelle Nachrichten
24.10.	Xbrane Biopharma AB: Xbrane Biopharma releases Interim Report for January-September 2024	Xbrane Biopharma AB's (publ.) ("Xbrane") Interim Report for January-September 2024, is as of today, available on the Company's website, www.xbrane.com. FINANCIAL OVERVIEWTHIRD QUARTER 2024*• Revenue... ► Artikel lesen
21.10.	Xbrane Biopharma AB: Xbrane Provides Update On The Ongoing Out-licensing Of Xdivane (nivolumab Biosimilar Candidate) And Xb003 (cimzia Biosimilar Candidate) And Its Financial Position	Xbrane Biopharma AB (publ) ("Xbrane" or the "Company") is, as communicated on August 12th, actively seeking partners for its biosimilar candidates Xdivane and XB003. The company has reached agreement... ► Artikel lesen
27.09.	Xbrane Biopharma AB: Xbrane provides update from Scientific Advice with US FDA on Xdivane (Opdivo biosimilar candidate)	Xbrane Biopharma AB (publ) ("Xbrane" or the "Company") has received scientific advice from the US Food and Drug Administration (FDA) on the development of its Opdivo® biosimilar candidate Xdivane. FDA... ► Artikel lesen
28.08.	Xbrane Biopharma AB: Xbrane Biopharma releases Interim Report for January-June 2024	Xbrane Biopharma AB's (publ.) ("Xbrane") Interim Report for January-June 2024, is as of today, available on the Company's website, www.xbrane.com. FINANCIAL OVERVIEWSECOND QUARTER 2024*• Revenue amounted... ► Artikel lesen
12.08.	Nasdaq Stockholm AB: Xbrane Biopharma AB ges observationsstatus / Xbrane Biopharma AB receives observation status	Idag, den 12 augusti 2024 offentliggjorde Xbrane Biopharma AB ("Bolaget") ett pressmeddelande med information om att Bolagets rörelsekapital beräknas räcka till slutet av oktober 2024. Enligt regelverket... ► Artikel lesen

Zeit

Aktuelle Nachrichten

24.10.

Xbrane Biopharma AB: Xbrane Biopharma releases Interim Report for January-September 2024

Xbrane Biopharma AB's (publ.) ("Xbrane") Interim Report for January-September 2024, is as of today, available on the Company's website, www.xbrane.com. FINANCIAL OVERVIEWTHIRD QUARTER 2024*• Revenue...
► Artikel lesen

21.10.

Xbrane Biopharma AB: Xbrane Provides Update On The Ongoing Out-licensing Of Xdivane (nivolumab Biosimilar Candidate) And Xb003 (cimzia Biosimilar Candidate) And Its Financial Position

Xbrane Biopharma AB (publ) ("Xbrane" or the "Company") is, as communicated on August 12th, actively seeking partners for its biosimilar candidates Xdivane and XB003. The company has reached agreement...
► Artikel lesen

27.09.

Xbrane Biopharma AB: Xbrane provides update from Scientific Advice with US FDA on Xdivane (Opdivo biosimilar candidate)

Xbrane Biopharma AB (publ) ("Xbrane" or the "Company") has received scientific advice from the US Food and Drug Administration (FDA) on the development of its Opdivo® biosimilar candidate Xdivane. FDA...
► Artikel lesen

28.08.

Xbrane Biopharma AB: Xbrane Biopharma releases Interim Report for January-June 2024

Xbrane Biopharma AB's (publ.) ("Xbrane") Interim Report for January-June 2024, is as of today, available on the Company's website, www.xbrane.com. FINANCIAL OVERVIEWSECOND QUARTER 2024*• Revenue amounted...
► Artikel lesen

12.08.

Nasdaq Stockholm AB: Xbrane Biopharma AB ges observationsstatus / Xbrane Biopharma AB receives observation status

Idag, den 12 augusti 2024 offentliggjorde Xbrane Biopharma AB ("Bolaget") ett pressmeddelande med information om att Bolagets rörelsekapital beräknas räcka till slutet av oktober 2024. Enligt regelverket...
► Artikel lesen

	Indizes	Kurs	%	News 24 h / 7 T	Aufrufe 7 Tage


	Aktien	Kurs	%	News 24 h / 7 T	Aufrufe 7 Tage


	Xetra-Orderbuch


	Fonds	Kurs	%


	Devisen	Kurs	%


	Rohstoffe	Kurs	%


	Themen	Kurs	%



Erweiterte Suche

XBRANE BIOPHARMA AB

Nasdaq Stockholm AB: Delisting of paid subscription units in Xbrane Biopharma AB